PRIMARY OBJECTIVES:~I. To assess the efficacy nivolumab administered in the adjuvant setting in patients with resected stage IIB or stage IIC cutaneous melanoma.~SECONDARY OBJECTIVES:~I. To evaluate and estimate the median duration of overall survival (OS) in stage IIB-IIC melanoma patients.~II. To evaluate and estimate the median duration of distant metastases-free survival (DMFS) in stage IIB-IIC melanoma patients.~III. To assess safety and toxicity using Common Terminology Criteria for Adverse Events (CTCAE) version (V)5.~IV. To assess quality of life using the Functional Assessment of Cancer Therapy-Melanoma (FACT-M) quality of life instrument.~TERTIARY OBJECTIVES:~I. To assess and compare clinical, histological, immunological and molecular panels as prognostic and predictive biomarkers.
This phase II trial studies how well nivolumab works in treating patients with stage IIB-IIC melanoma that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.